Total results651
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| JAK3 | P52333 | Tyrosine-protein kinase JAK3 (EC 2.7.10.2) (Janus kinase 3) (JAK-3) (Leukocyte janus kinase) (L-JAK) | Cancer-related genesDisease related genesEnzymes | SCID | Adhesion and uptake mediationClinical-translation mediationImmune mediation | 3 | 0.53 | |||
| KCC2B | Q13554 | Calcium/calmodulin-dependent protein kinase type II subunit beta (CaM kinase II subunit beta) (CaMK-II subunit beta) (EC 2.7.11.17) | Disease related genesEnzymesHuman disease related genes | Intellectual disability | Fusion and delivery mediationImmune mediationReceptor-signaling mediation | 3 | 0.53 | |||
| LMOD2 | Q6P5Q4 | Leiomodin-2 (Cardiac leiomodin) (C-LMOD) (Leiomodin) | Disease related genesPredicted intracellular proteins | Cardiomyopathy | Fusion and delivery mediation | 3 | 0.53 | |||
| NMDE2 | Q13224 | Glutamate receptor ionotropic, NMDA 2B (GluN2B) (Glutamate [NMDA] receptor subunit epsilon-2) (N-methyl D-aspartate receptor subtype 2B) (NMDAR2B) (NR2B) (N-methyl-D-aspartate receptor subunit 3) (NR3) (hNR3) | Disease related genesFDA approved drug targetsHuman disease related genes | 3 | EpilepsyIntellectual disability | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 3 | 0.53 | ||
| OX2G | P41217 | OX-2 membrane glycoprotein (CD antigen CD200) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Acute myeloid leukaemiaMature B-cell leukaemiaSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 3 | 0.53 | ||
| 5HT1B | P28222 | 5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (S12) (Serotonin 1D beta receptor) (5-HT-1D-beta) (Serotonin receptor 1B) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Alzheimer diseaseAnxiety disorderAttention deficit hyperactivity disorder | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 2 | 0.53 | ||
| 5HT2B | P41595 | 5-hydroxytryptamine receptor 2B (5-HT-2B) (5-HT2B) (Serotonin receptor 2B) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Anxiety disorderAttention deficit hyperactivity disorderCoronary atherosclerosis | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | ||
| 5HT7R | P34969 | 5-hydroxytryptamine receptor 7 (5-HT-7) (5-HT7) (5-HT-X) (Serotonin receptor 7) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Alzheimer diseaseAttention deficit hyperactivity disorderBipolar disorder | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 2 | 0.53 | ||
| AA2BR | P29275 | Adenosine receptor A2b | 7 | Alzheimer diseaseAsthmaBreathing abnormality | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 | |||
| ACE | P12821 | Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-converting enzyme, soluble form] | Candidate cardiovascular disease genesCD markersDisease related genes | 1 | AsthmaCardiovascular diseaseChronic kidney disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 |